Cargando…
Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
INTRODUCTION: Long Acting Buprenorphine (LAB) – Buvidal (CAM2038) – is a prolonged release treatment for opioid dependence in adults. Its extensive use was funded by Welsh Government during the pandemic in Wales and it has been found to be a significantly better than oral medications in improving qu...
Autores principales: | Melichar, J., Graver, F., Parimelalagan, L., Lewis, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563216/ http://dx.doi.org/10.1192/j.eurpsy.2022.855 |
Ejemplares similares
-
Significantly improved outcomes – both in retention and CGI scores - using Long Acting Buprenorphine (LAB-Buvidal) versus treatment as usual for Opioid Dependence in Wales during the Pandemic
por: Melichar, J., et al.
Publicado: (2022) -
Systematic Review of the Safety and Tolerability of Injectable Prolonged-Release Buprenorphine (Buvidal) in Adults With Opioid Dependence
por: Williams, Laura, et al.
Publicado: (2023) -
The Patient's Guide to Buvidal: A Service Improvement of a Digital Repository of Patient Information for Patients Taking Buvidal in Wales
por: Ward, Devon
Publicado: (2023) -
Service evaluation of long acting buprenorphine subcutaneous injection (BUVIDAL) in the west Lothian community addictions service
por: Martin, Amy
Publicado: (2021) -
Tramadol Versus Codeine in Hand Surgery
por: Tulipan, Jacob, et al.
Publicado: (2022)